On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Predictive Oncology Inc. (NASDAQ: POAI) Stands to Benefit from Explosive Growth of Precision Medicine

  • Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient
  • Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment
  • Predictive Oncology has been forerunner in its field, both through Helomics division’s smart tumor profiling platform as well as TumorGenesis subsidiary, which creates the tools used in ovarian cancer research
  • TumorGenesis has begun to commercialize intellectual property, having received first order for unique ovarian cancer cell culture media in June 2020

In the summer of 2018, 49-year-old Star Dolbier arrived at the University of Maryland Greenebaum Cancer Center with a large mass on her left lung; at the time, the five-year survival rate for her type of advanced lunch cancer was only six percent (https://nnw.fm/NoZKP). However, tests carried out on tiny fragments of tumor DNA allowed her to be treated with a novel drug treatment, virtually eradicating the cancer from her system only 18 months later. In addition to looking at mutations in tumor DNA, oncologists have increasingly begun using laboratory-grown tumors or cancer cells to test the effectiveness of different cancer drugs, thereby helping determine the best course of treatment for a specific individual. Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division.

Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

The use of precision medicine in oncology – a field wherein doctors use insights drawn from laboratory-grown cancer cells and their patients’ DNA to prescribe personalized drug treatments, has seen exponential growth in recent years. Rather than resorting to a one-size-fits-all standard of care, oncologists can prescribe more personalized medicines, with last year seeing the approval of over two dozen such drugs (https://nnw.fm/gHyCM); over the next two years, forecasts predict that the number of new personalized treatments will outnumber those developed for the general population.

POAI’s wholly owned TumorGenesis subsidiary specializes in the field of ovarian cancer, developing tools (kits, reagents and specialty cell-culture media) to grow tumors and cancer cells in a manner that mimics the patient’s own body.  TumorGenesis’ proprietary Oncology Capture Technology Platform isolates and cultures the patient’s heterogenous tumor sample, providing a much better model of the tumor outside the body (ex vivo). These improved ex-vivo tumor models can then be used by researchers to investigate cancer and by clinicians to develop patient-specific treatment plans (https://nnw.fm/5W4XP). TumorGenesis announced that the division had sold its first order of its unique ovarian cancer cell culture media to a New England-based university seeking to carry out research utilizing laboratory-grown cancer cells.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217